Global 1000 Conference University Startup Portfolio Andrew R.O. Watson, PhD, CLP March 19, 2014
OHSU Research at OHSU (Fiscal Year 2013): • $340.3 Million in Research Expenditures • $220.9M from NIH • $ 42.5M from industry • $ 41.5M from other US Federal Agencies • $ 34.2M from private organizations • $ 1.2M from nonfederal government
Research Strengths at OHSU • Vaccine development • Therapeutic approaches against serious infectious diseases • Magnetic resonance techniques and technologies • Non-human primate models • Neuroscience • Rare diseases • Spatial Systems Biomedicine – molecular medicine in four dimensions • Cardiovascular • Cancer • The $1B Knight Cancer Challenge
Commercialization at OHSU Other FY10 FY11 FY12 FY13 FY98-FY09 MedTech 0 10 20 30 40 50 BioTech Cumulative # Startups since 1998
www.aronorabio.com Developing safer anti-thrombotics without the side effects of all currently marketed treatments Three products in development: stand-alone emergency use, use when bleeding risk is moderate, and in conditions that are intrinsically accompanied with bleeding Aronora is the recipient of multiple awards from the NIH as well as a participant in Bayer’s Grants4Targets initiative Operations in Portland, OR and Bayer’s CoLaborator in San Francisco, CA Aronora seeks private investment, strategic partnerships, and out-licensing opportunities that are consistent with their business strategy
www.artielle.com Developing a new class of molecules known as Recombinant T cell receptor Ligands (RTLs) to treat autoimmune inflammatory diseases Lead compound, which has received Orphan Drug status from the US FDA, is entering Phase II clinical trials for Multiple Sclerosis funded by the US Department of Veterans Affairs Operations in Tigard, OR and San Mateo, CA Next goal after phase II: a partnership with a pharmaceutical company to help bring the lead product to market
www.gamma-therapeutics.com Developing a novel class of biopharmaceutical and diagnostic test solutions for the cardiovascular disease industry GammaCoeur TM – Measurable cardiovascular disease Dx assay for prognosis and preventative care GammaSeal TM – High strength, natural surgical sealant for large artery vascular surgery or wound repair Gammarin TM – Non-immunogenic, short acting anti-coagulant blood thinner for post- surgical venous thromboembolism control Operations in Portland, OR Seeking $1.5M Series A Round focused on GammaCoeur development
www.reeldx.com The internet’s first library of real patient video case studies, viewable on any web-enabled device - including tablets and smartphones. Current libraries include Pediatrics cases and Emergency Medicine cases – libraries launched in 2013 The founders are both proven pioneers in the fields of video diagnosis and online education. One, a clinician, has perfected the method of capturing relevant clinical video content. The other has been at the forefront of two important online trends – health information and online learning. Operations in Portland, OR Next: Creation and growth of additional libraries, subscribership and new products
Thank You Andrew R.O. Watson, PhD, CLP Director, Technology Transfer watsonan@ohsu.edu (503) 494-8309
Recommend
More recommend
